Grifols is expected to report consensus revenue of $2.22 billion and an EPS of $0.28, with the stock currently trading at $7.61 compared to an average analyst price target of $10.00. The central focus for investors this quarter is the company's leverage ratio as it works to restore balance sheet stability.
Recent performance has been supported by the professionalization of management under CEO Nacho Abia and the successful refinancing of all 2027 debt maturities. Market sentiment remains cautious but improving as the company delivers on its 2026 deleveraging targets and explores a potential U.S. listing for its Biopharma division.